We carried out a phase I trial of the vascular endothelial growth factor inhibitor pazopanib and the histone deacetylase inhibitor vorinostat to determine the safety and efficacy. Because these agents are known to target factors activated by TP53 mutation and facilitate mutant p53 degradation, a subgroup analysis may be interesting in patients with TP53 mutant malignancies.
introduction
Tumor hypoxia occurs when a solid tumor outgrows the existing vasculature [1] and can be caused by antiangiogenic therapy [2] , which increases histone deacetylase (HDAC) activity [3] , and enhances hypoxia-inducible factor 1α (HIF-1α) stability and HIF-1α transactivation function mediated by activated HDAC1 and 3 [4] . The hypoxia-mediated increase of HIFs is critical to the establishment and progression of many cancers via HIF-dependent activation of genes that allow cancer cells to survive, metastasize, and develop resistance to antiangiogenic treatment [5, 6] .
Among many candidate pathways, the vascular endothelial growth factor (VEGF) pathway serves an important survival function in cancer cells with a TP53 mutation [7, 8] . TP53 mutations in tumor cells increase the level of HIF-1α and augment HIF-1α-dependent transcriptional activation of the VEGF gene in response to hypoxia [9] . In addition, vorinostat preferentially kills TP53 mutant cancer cells both in cell cultures and in xenograft models through HDAC5 that is a critical player in the p53 acetylation network [10, 11] , and HDAC6 and 8 that facilitate mutant p53 degradation via interaction with heat shock protein 90 [12] [13] [14] . Exploration of HDAC inhibitor-mediated downregulation of HIFs and mutant p53 for targeting tumor resistance to antiangiogenic therapy is supported by preclinical and retrospective clinical findings. We therefore conducted this first phase I trial (NCT01339871) combining pazopanib and vorinostat in patients with advanced malignancies.
patients and methods

patients and treatment
Patients 13 years of age or older were eligible if they had a histologically confirmed advanced malignancy, with no previous standard therapy that improved survival for at least 3 months. All participants had measurable or evaluable disease that had progressed before study entry and an ECOG (East Cooperative Oncology Group) performance status of 2 or better [15] . Additional eligibility criteria included adequate marrow function (absolute neutrophil count ≥1000/μl and platelet count ≥75 000/μl), serum creatinine ≤2 times the upper limit of normal (ULN), total bilirubin ≤2.0 mg/dl, and alanine transaminase ≤2.5 or 5 × ULN if liver metastasis was present. Patients with the following conditions were excluded: poorly controlled hypertension; clinically significant cardiovascular disease; symptomatic involvement of the central nervous system; active fistula, ulceration, perforation, abscess, clinical bleeding, and/or gastrointestinal malabsorption; pregnancy or lactation; and unwillingness or inability to give informed consent.
The trial conducted at The University of Texas MD Anderson Cancer Center (MD Anderson) was approved by the Institutional Review Board. All patients had provided their informed consent before study entry. Daily treatment with oral pazopanib and vorinostat was administered until tumor progression, prohibitive toxicity, or patient withdrawal. Each cycle was 28 days.
evaluation of safety and efficacy
All patients who received at least one dose of any of the study agents were considered evaluable for drug safety and efficacy. The severity of adverse events was graded according to the Common Terminology Criteria for Adverse Events version 4.0 [16] . Dose-limiting toxicity (DLT) was defined as treatment-related grade 4 hematologic toxicity lasting >2 weeks, grade 4 nausea or vomiting lasting for >3 days, grade 4 fatigue and hypertension, or any other grade 3 or higher toxicity within the initial 28 days. If two of six had a DLT, then that dose level was declared to be above the maximum tolerated dose (MTD). Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 were used to characterize tumor responses [17] 10 [332-367] , n = 28) or Foundation Medicine (whole-exome sequencing, n = 8) using archival formalin-fixed, paraffin-embedded tissue blocks, or material from core biopsies of tumor tissues [18] [19] [20] .
statistical considerations
To test different dose combinations, we used a modified zone-based 3 + 3 design [21] . An additional three patients were allowed per dose level as needed for safety assessment. If benefit was observed in a specific type of cancer, a mini-expansion of up to 14 patients was permitted at the highest dose level considered to be safe at the time of patient entry [22] . Descriptive summary statistics were used to characterize demographics, safety, and antitumor activity. Categorical data were summarized using frequency and percentages. Continuous data were summarized by median with 95% confidence intervals (CI), and range. Differences in categorical variables were assessed by Fisher exact tests. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. PFS was time from enrollment to death or progression (whichever is first). Patients without evidence of progression or death were censored at the date of last radiographic assessment of progression. OS was time from enrollment to death or 30 June 2014, at which time the patients' data were censored. Log-rank tests were used to compare PFS and OS distributions between groups. The multivariate Cox regression model was used to examine risk factors related to outcomes without adjustment for a specific factor. Statistical inferences were based on two-sided tests at a significance level of P < 0.05. Statistical analyses were carried out using SPSS Statistics version 22 (IBM, Armonk, NY, USA).
results
patient characteristics
Patient characteristics are listed in Table 1 . A total of 78 patients were recruited to 11 dose levels. Patients were heavily pretreated with a median of three prior chemotherapy regimens. Half of the patients progressed after receiving VEGF inhibition-based therapy. Children (n = 6) were included since the study regimen might have a potential therapeutic value in pediatric cancers. Approximately 47% of the patients had metastatic sarcoma (n = 23) or metastatic colorectal cancer (CRC; n = 14).
safety
All 78 patients were evaluable for toxicity (Table 2 ). There were no treatment-related deaths. Four cases of DLT (grade 4 thrombocytopenia [n = 1], grade 3 diarrhea [n = 2], and grade 3 skin rash [n = 1]) were observed at levels 4B, 5A, and 5B. Dose reduction and patient withdrawal for toxicity frequently took place at levels 3A (17%, 1 of 6 patients), 3B (25%, 2 of 8), 3C (40%, 2 of 5), 4A (67%, 4 of 6), 4B (50%, 9 of 18), 4C (50%, 3 of 6), 5A (57%, 4 of 7), and 5B (57%, 4 of 7) . No MTD has been identified yet. Because of high-frequent dose reduction and patient withdrawal from treatment-related toxicity, planned dose escalation to level 6 was discontinued. Level 4B was chosen for dose expansion, and DLT was observed in 2 (11%) of the 18 patients. Clinically significant ≥grade 2 adverse events included fatigue, thrombocytopenia, neutropenia, nausea, vomiting, diarrhea, and skin rashes.
efficacy antitumor activity for all enrolled patients. All 78 patients were evaluable for efficacy. Four patients (5%) had partial responses (PRs), and 11 patients (14%) had stable disease for at least 6 months (SD ≥6 months). Thus, a clinical benefit defined as SD ≥6 months/PR was achieved in 19% of patients. The median PFS and OS for the 78 patients were 2.2 months (95% CI 1.8-2.6) and 8.9 months (6.7-11.1), respectively. The univariate analysis revealed no difference in SD ≥6 months/PR, PFS, or OS between patients (n = 39) who had previous exposure to a VEGF inhibitor (21%, 2.8 months [1.8-3.8], and 8.2 months [5.1-11.3], respectively) and those (n = 39) who had not (21%, 2.0 months [1.7-2.3], and 9.6 months [6.6-12.6], respectively; P > 0.05 for all comparisons). In the multivariate analysis using the Cox regression model for determining SD ≥6 months/PR using 15 independent baseline potential risk factors at the time of study entry (Table 3) , hypoalbuminemia (P = 0.027) and undetected hotspot TP53 mutation (P = 0.048) were significant independent variables that predicted a lower rate of SD ≥6 months/PR.
antitumor activity for patients tested for hotspot TP53 mutations.
Thirty-six patients were tested for TP53 mutations (hotspot, n = 28 and whole-exome, n = 8). Table 4 lists the major clinical characteristics and outcomes for patients with detected hotspot TP53 mutations (n = 11, 31%) and patients with undetected hotspot TP53 mutations (n = 25, 69%): R175H and H179R (two patients each), as well as G245S, H193R, R213*, R273C, and V216M (one each). Whole-exome sequencing revealed two TP53 mutations: A159fs (a part of the hotspots) and DNAbinding domain truncation (outside the hotspots). Compared with the undetected TP53 mutations (Figure 1) , the detected hotspot TP53 mutations were associated with a favorably higher rate of SD ≥6 months/PR ( antitumor activity for sarcoma or CRC patients tested for hotspot TP53 mutations. Of the 23 patients with metastatic sarcoma, 6 had SD ≥6 months/PR (26%, 2 PRs and 4 SD ≥6 months) after they received treatment with pazopanib and vorinostat. The median PFS and OS for these 23 patients were 2.0 months (1.8-2.2) and 8.3 months (5.9-10.7), respectively. Of the 14 patients with metastatic CRC, 2 had SD ≥6 months (14%). The median PFS and OS for these 14 patients were 2.0 months (1.5-2.6) and 6.8 months (0-17.7), respectively. The outcomes for patients with metastatic sarcoma or CRC were similar to those for the 41 patients with other advanced malignancies (P > 0.05 for all subgroups). The hotspot TP53 mutations were detected in 6 of the 17 patients (35%). As summarized in Table 4 and Figure 2 , five of the six sarcoma or CRC patients with detected hotspot TP53 mutations had SD ≥6 months/PR (83%, one PR and four SD ≥ 6 months) after treatment with pazopanib and vorinostat, associated with the median PFS and OS of 6.5 months (3.0-9.0) and 19.8 months (8.2-31.4), respectively. These results were significantly better than those for patients with undetected hotspot TP53 mutations (n = 11): one SD ≥6 months (9%, P = 0.005), the median PFS of 2.0 months (1.8-2.2, P = 0.017), and the median OS of 7.2 months (0.4-14; P = 0.015).
discussion
Pazopanib was approved for the treatment of advanced renal cell carcinoma and soft tissue sarcoma since it led to a significantly longer PFS than placebo [23] , whereas vorinostat was approved for cutaneous T-cell lymphoma [24] . Pazopanib synergized with vorinostat to kill tumor cells [25] , providing the rationale to conduct this pilot study. Our study represents an excellent example of how, by identifying patient subgroups most likely to respond to treatment, phase I trials can help guide drug development. In unselected 78 phase I patients with different pathological diagnoses, treatment with pazopanib and vorinostat did not lead to antitumor activity (5% PR and 14% SD ≥6 months) in a meaningful way. However, our findings with respect to detected hotspot TP53 mutation status are highly significant: patients with a hotspot TP53 mutation had a markedly higher rate of SD ≥6 months/PR, longer median PFS, and median OS than those without a hotspot TP53 mutation. Furthermore, of the patients with metastatic sarcoma or metastatic CRC, those with a hotspot TP53 mutation had significantly longer median PFS and median OS, and a significantly higher rate of SD/PR than those without a hotspot TP53 mutation. These findings indicate that treatment with pazopanib and vorinostat should be further evaluated in cancer patients with a hotspot TP53 mutation, especially those with metastatic sarcoma or metastatic CRC. The tumor suppressor gene TP53 is mutated in many human tumors, and a variety of TP53 mutations (missense, frameshift [fs], or nonsense [*], leading to gain or loss of function) have been identified during tumorigenesis, tumor development, and metastasis [26] . Cancer cells with mutated p53 have accelerated tumor growth associated with increased VEGF expression and neovascularization [27] , which serves an important survival pathway [7, 8] , resulting in a therapeutic advantage of VEGF inhibition in patients with p53 mutant malignancies [28] . Facilitation of mutant p53 degradation [12] [13] [14] and downregulation of VEGF inhibition-mediated increased HIFs via HDAC inhibition [4, 9, 29] support the use of this combination in patients with TP53 mutant malignancies [25] .
In view of our findings, one important question might be what types of TP53 mutations are associated with better clinical outcomes in response to treatment with pazopanib and vorinostat. In agreement with the previous reports that the majority of TP53 mutations are localized in exons 5-8, which encode the DNA-binding domain, all nine TP53 mutations detected in our study were located in these regions, and were associated with either loss of function (A159fs, R213*, and DNA-binding domain truncation) or gain of function (R175H, H179R, H193R, V216M, G245S, and R273C). Since only 11 patients were found to have detected hotspot TP53 mutations out of 36 patients tested (∼31%), further evaluation in larger cohorts of patients with hotspot TP53 mutations is needed to identify potential biomarkers of treatment response to pazopanib and vorinostat. In considering the clinical relevance of our findings, several limitations should be borne in mind. First, the selection bias associated with the eligibility criteria may limit the generalizability of our findings, as it does for many clinical trials. Secondly, the small sample sizes in subgroup analyses limited the validity of statistical assessments of individual pathological diagnoses. Thirdly, an optimal phase II dose was difficult to establish, in part because only the daily dosing schedule was tested.
In conclusion, the regimen of oral pazopanib at 600 mg daily in combination with oral vorinostat at 300 mg daily was well tolerated, although a dose reduction may be eventually needed over time for better tolerance. Further evaluation of the regimen is warranted in patients with TP53 mutant advanced cancer, especially in patients with metastatic sarcoma or metastatic CRC. Also, the traditional strategy of including unselected cancer patients may not meet the challenges of the current landscape of early drug development.
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